FDA Approves Alectinib for Early-Stage ALK+ NSCLC

News
Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

FDA

FDA

The FDA has approved alectinib (Alecensa) for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) with tumors that are at least 4 cm or node-positive, as detected by an FDA-approved test.

The approval is based on results from the phase 3 ALINA trial (NCT0346076) assessing alectinib vs chemotherapy for patients with early-stage ALK-positive NSCLC. The risk of death or recurrence was reduced by 76% (HR, 0.24; 95% CI, 0.13-0.43; P <.0001). The disease-free survival (DFS) was also observed in an exploratory analysis and saw an improvement (HR, 0.22; 95% CI, 0.08-0.58).

“The approval of [alectinib] marks a pivotal moment for [patients with] newly diagnosed with early-stage ALK-positive lung cancer, who until now, were not able to receive ALK-specific therapy,” said Ken Culver, director of Research and Clinical Affairs at ALK Positive, Inc. “These patients, who are typically diagnosed at a younger age, often face recurrence and have a higher risk of developing brain metastases than those with other types of NSCLC. Now, with this significant advance, it is more important than ever that all people diagnosed with early-stage lung cancer undergo testing for ALK and other recommended biomarkers to receive the treatment most appropriate for them.”

The study enrolled 257 patients who were randomly assigned to receive either alectinib or chemotherapy. The primary end point was DFS and secondary end points included overall survival, central nervous system DFS, and the amount of patients with adverse effects.

Alectinib was designed to prevent lung cancer occurrence after it had been removed by surgery, or to treat patients where the tumor has metastasized.

References

  1. FDA approves Genentech's Alecensa as first adjuvant treatment for people with ALK-positive early-stage lung cancer. News release. Genentech. April 18, 2024. Accessed April 18, 2024. https://shorturl.at/zSV29
  2. Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024;390(14):1265-1276. doi:10.1056/NEJMoa2310532
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
Related Content